Ichthyosis Pipeline Analysis Report 2026

Report Coverage

The Ichthyosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into ichthyosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ichthyosis. The ichthyosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ichthyosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ichthyosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ichthyosis.

Read more about this report - Request a Free Sample

Ichthyosis Pipeline Outlook

The ichthyosis treatment pipeline is evolving from purely symptomatic management toward disease-modifying approaches. Currently, standard care primarily relies on topical emollients, keratolytics, and supportive barrier-repair therapies, with no FDA-approved targeted treatments available.

Ichthyosis treatment innovation is now focused on correcting underlying molecular defects. In October 2025, Azitra, Inc. announced positive preclinical results for its ATR-01 program targeting ichthyosis vulgaris. The engineered ATR01-616 strain successfully delivered functional filaggrin through human skin and reduced transepidermal water loss in preclinical models. These findings, presented at BIO-Europe 2025, support progression toward first-in-human studies planned for 2026.

Ichthyosis Epidemiology

Ichthyosis encompasses multiple genetic skin disorders, with ichthyosis vulgaris being the most common and X-linked ichthyosis the second most prevalent form. X-linked ichthyosis affects males predominantly, with an incidence ranging from 1 in 2,500 to 1 in 6,000 males worldwide and equally affects all ethnic groups. Symptoms appear at birth in about 15-20% of cases, with the remainder developing scaling during early infancy. Although definitive treatment does not exist, these conditions are lifelong and significantly impact quality of life due to chronic dry, scaly skin and associated complications.

Ichthyosis – Pipeline Therapeutic Assessment

Ichthyosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II dominates with 38% of trials, followed by phase I at 24%, phase III 19%, early-phase I 10%, and phase IV 10%. Overall, this distribution highlights a balanced pipeline with strong mid- to late-stage clinical development activity in ichthyosis therapies.

Ichthyosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the ichthyosis pipeline analysis include monoclonal antibodies, small molecules, and peptides. The ichthyosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ichthyosis. In August 2025, Quoin Pharmaceuticals reported Q2 2025 results, highlighting positive six-month clinical data from an ongoing pediatric Netherton syndrome study and FDA clearance of a second pivotal trial for QRX003. The company also announced initial positive results in peeling skin syndrome, received Orphan Drug designation in Europe, and earned U.S. Rare Pediatric Disease designation for QRX003.

Ichthyosis Clinical Trials – Key Players

The EMR report for the ichthyosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ichthyosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ichthyosis clinical trials:

• Azitra Inc.
• BioCryst Pharmaceuticals
• GlaxoSmithKline
• Janssen Scientific
• Quoin Pharmaceuticals
• Biocodex
• Kerecis Ltd.
• Patagonia Pharma
• Crown Laboratories, Inc.
• Bristol Myers Squibb

Ichthyosis – Emerging Drugs Profile

Key Questions Answered in the Ichthyosis Pipeline Insight Report

• Which companies/institutions are leading the ichthyosis drug development?
• Which company is leading the ichthyosis pipeline development activities?
• What is the current ichthyosis commercial assessment?
• What are the opportunities and challenges present in the ichthyosis pipeline landscape?
• What is the efficacy and safety profile of the ichthyosis pipeline drugs?
• Which company is conducting major trials for ichthyosis drugs?
• Which companies/institutions are involved in ichthyosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in ichthyosis?

Reasons To Buy This Report

The Ichthyosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ichthyosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ichthyosis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Ichthyosis Epidemiology Forecast

Lamellar Ichthyosis Epidemiology Forecast

Netherton Syndrome Market